NASDAQ:RYTM Rhythm Pharmaceuticals Q3 2025 Earnings Report $100.82 +0.61 (+0.61%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$100.87 +0.05 (+0.05%) As of 10/10/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Rhythm Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$0.72Beat/MissN/AOne Year Ago EPSN/ARhythm Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$50.71 millionBeat/MissN/AYoY Revenue GrowthN/ARhythm Pharmaceuticals Announcement DetailsQuarterQ3 2025Date11/4/2025TimeBefore Market OpensConference Call DateTuesday, November 4, 2025Conference Call Time5:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Rhythm Pharmaceuticals Earnings HeadlinesShould You Expect Robust Growth Potential for Rhythm Pharmaceuticals (RYTM) Ahead?October 3, 2025 | insidermonkey.comHC Wainwright & Co. Maintains Rhythm Pharmaceuticals (RYTM) Buy RecommendationSeptember 29, 2025 | msn.comURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash before 2025 ends.October 11 at 2:00 AM | StockEarnings (Ad)JMP Securities Maintains Rhythm Pharmaceuticals (RYTM) Market Outperform RecommendationSeptember 26, 2025 | msn.comRhythm Pharmaceuticals price target raised to $142 from $135 at Citizens JMPSeptember 25, 2025 | msn.comRhythm Pharmaceuticals price target raised to $122 from $109 at Morgan StanleySeptember 24, 2025 | msn.comSee More Rhythm Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rhythm Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rhythm Pharmaceuticals and other key companies, straight to your email. Email Address About Rhythm PharmaceuticalsRhythm Pharmaceuticals (NASDAQ:RYTM) is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation. The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1. Rhythm has advanced multiple Phase 3 clinical trials for setmelanotide and is pursuing regulatory approvals in both the United States and the European Union. In addition to its lead program, the company is exploring opportunities in related rare obesity indications and branching into other metabolic disorders tied to melanocortin pathway dysfunction. Founded in 2013 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals is led by a management team with extensive experience in drug development, regulatory strategy and commercialization of therapies for rare diseases. The company maintains a robust intellectual property portfolio around its peptide technology and collaborates with academic institutions and patient advocacy groups to advance understanding of rare genetic forms of obesity. Rhythm’s work underscores a commitment to precision medicine approaches that address the root causes of metabolic disorders.View Rhythm Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings Fastenal (10/13/2025)America Movil (10/14/2025)Wells Fargo & Company (10/14/2025)Citigroup (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)The Goldman Sachs Group (10/14/2025)BlackRock (10/14/2025)ASML (10/15/2025)Kinder Morgan (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
